• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of October 18

Video

Here are the top 5 biosimilar articles for the week of October 18, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 18, 2021.

Number 5: Hopes that insulin biosimilars can improve access and affordability will be tested by Express Scripts’ plan to give preferred formulary status to Semglee, a long-acting insulin that is interchangeable with Lantus.

Number 4: Switching between reference adalimumab (Humira) and its approved biosimilars results in no differences in efficacy, safety, and immunogenicity, investigators in Spain have concluded following a systematic review of available studies.

Number 3: An additional 1.2 million patients could benefit from biosimilars by 2025, according to a specialty pharmacy report by CoverMyMeds, a division of McKesson. The report discusses payer/pharmacy benefit manager consolidation, patient adherence, white bagging, and other issues common to specialty pharma.

Number 2: In a recent interview, Gary Lyman, MD, MPH, an oncologist and hematologist and public health researcher with the Hutchinson Institute for Cancer Outcomes Research, compares the uptake of biosimilars for cancer care and other conditions and provides insight on how uptake could be improved.

Number 1: The FDA has approved an interchangeable designation for Boehringer Ingelheim’s adalimumab biosimilar Cyltezo, which was originally approved in August 2017 and is scheduled to go on the market on July 1, 2023.

To read all of these articles and more, visit centerforbiosimilars.com.

Newsletter

Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.

Recent Videos
Here are the top 5 biosimilar articles for the week of July 21, 2025.
Here are the top 5 biosimilar articles for the week of July 14, 2025.
Here are the top 5 biosimilar articles for the week of July 7, 2025.
Here are the top 5 biosimilar articles for the week of June 30, 2025.
Canavan & O’Dell
Here are the top 5 biosimilar articles for the week of June 23, 2025.
Here are the top 5 biosimilar articles for the week of June 16, 2025.
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Here are the top 5 biosimilar articles for the week of June 9, 2025.
Here are the top 5 biosimilar articles for the week of June 2, 2025.
Related Content
© 2025 MJH Life Sciences

All rights reserved.